Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Withdrawal Trial of TAK-861 in Narcolepsy Type 1
2024-519466-44-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in narcolepsy type 1 (NT1) comparing TAK-861 arm with Placebo arm (2 arms). Primary endpoint: Time to loss of response in Epworth Sleepiness Scale (ESS) during randomized withdrawal period. Planned start Feb 2026; status: authorised.
02
Drugs
oveporexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on 2024-519466-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519466-44-00.